Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Investigation of Dysregulated Signaling in MPD Via Multiparameter Phospho-specific Flow Cytometry

This study has been terminated.
Information provided by (Responsible Party):
Stanford University Identifier:
First received: June 14, 2010
Last updated: June 29, 2016
Last verified: June 2016
The objective of this study is to better understand the underlying pathogenetic mechanisms of MPDs. We will collect peripheral blood samples from MPD patients and utilize multiparameter phospho-specific flow cytometry to investigate dysregulated signaling in blood cells from these patients. This will provide deeper insights into the pathogenesis of MPDs and may lead to the identification of novel targets for therapeutic intervention.

Myeloproliferative Disorders
Myeloproliferative Disorders (MPD)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigation of Dysregulated Signaling in Myeloproliferative Disorders Via Multiparameter Phospho-specific Flow Cytometry

Resource links provided by NLM:

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples Without DNA
blood and bone marrow

Enrollment: 10
Study Start Date: September 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).

Inclusion Criteria:Any patient who carries a diagnosis of a myeloproliferative disorder (MPD).

Exclusion Criteria:Any patient who is not willing to give consent.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01144780

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Jason Robert Gotlib Stanford University
Principal Investigator: Stephen Tracy Oh Stanford University
  More Information

Responsible Party: Stanford University Identifier: NCT01144780     History of Changes
Other Study ID Numbers: HEMMPD0011
SU-07092009-3060 ( Other Identifier: Stanford )
Study First Received: June 14, 2010
Last Updated: June 29, 2016

Additional relevant MeSH terms:
Myeloproliferative Disorders
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases processed this record on May 25, 2017